
Major Scope
- Lung Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Breast Cancer
- Prostate Cancer
- Liver Cancer
- Leukemia
- Bladder Cancer
- Kidney Cancer
- Endometrial Cancer
- Oncology Case Reports
- Radiation Therapy
Abstract
Citation: Clin Oncol. 2017;2(1):1230.DOI: 10.25107/2474-1663-v2-id1230
Postoperative Radioactive Iodine for Differentiated Thyroid Cancer: A Historical Perspective
TW Chan, JR Hurley and TJ Fahey
Department of Surgery, Section of Endocrine Surgery, Weill Cornell Medical College, USA
Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Weill Cornell Medical College, USA
PDF Full Text Review Article | Open Access
Abstract:
Radioactive iodine has been used in differentiated thyroid cancer for postoperative thyroid remnant ablation for several decades, yet its indications remain controversial. Because the potential administration of postoperative RAI plays an important role in surgical decision-making, understanding the current indications for postoperative RAI is critical in the global management of differentiated thyroid cancer. This review examines the changing indications for postoperative radioiodine from its introduction to the current guidelines.
Keywords:
Cite the Article:
Chan TW, Hurley JR, Fahey TJ. Postoperative Radioactive Iodine for Differentiated Thyroid Cancer: A Historical Perspective. Clin Oncol. 2017; 2: 1230.
Journal Basic Info
- Impact Factor: 3.231**
- H-Index: 11
- ISSN: 2474-1663
- DOI: 10.25107/2474-1663
- PubMed NLM ID: 101705590